@article{9d257cc9fb3848bcaa0fde4e9c796d61,
title = "The measurement properties of tests and tools used in cystic fibrosis studies: A systematic review",
abstract = "There is no consensus on how best to measure responses to interventions among children and adults with cystic fibrosis (CF). We have systematically reviewed and summarised the characteristics and measurement properties of tests and tools that have been used to capture outcomes in studies among people with CF, including their reliability, validity and responsiveness. This review is intended to guide researchers when selecting tests or tools for measuring treatment effects in CF trials. A consensus set of these tests and tools could improve consistency in how outcomes are captured and thereby facilitate comparisons and synthesis of evidence across studies.",
author = "Charlie McLeod and Jamie Wood and Allison Tong and Andr{\'e} Schultz and Richard Norman and Sherie Smith and Blyth, \{Christopher C.\} and Steve Webb and Smyth, \{Alan R.\} and Snelling, \{Thomas L.\}",
note = "Funding Information: Support statement: Funding was received from Perth Children{\textquoteright}s Hospital Foundation (grants 9772 and 9757), National Health and Medical Research Council (GNT1111657) and Wesfarmers Centre for Vaccines and Infectious Diseases. Funding information for this article has been deposited with the Crossref Funder Registry. Funding Information: Acknowledgements: This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors. C. McLeod is supported by an NHMRC post-graduate scholarship (GNT1150996), and top-up grants from the Wesfarmers Centre and the Perth Children{\textquoteright}s Hospital Foundation (9772 and 9757). T.L. Snelling is supported by a Career Development Fellowship from the National Health and Medical Research Council (GNT1111657). C.C. Blyth is also supported by the National Health and Medical Research Council (1111596/1173163). Funding Information: Conflict of interest: C. McLeod has nothing to disclose. J. Wood has nothing to disclose. A. Tong has nothing to disclose. A. Schultz reports personal fees from Vertex Pharmaceuticals, outside the submitted work. R. Norman has nothing to disclose. S. Smith has nothing to disclose. C.C. Blyth has nothing to disclose. S. Webb has nothing to disclose. A.R Smyth reports grants from Vertex, speaker honoraria and expenses from TEVA and Novartis, and personal fees from Vertex, outside the submitted work. In addition, A.R. Smyth has a patent “Alkyl quinolones as biomarkers of Pseudomonas aeruginosa infection and uses thereof” issued. T.L. Snelling has nothing to disclose. Publisher Copyright: {\textcopyright} The authors 2021.",
year = "2021",
month = jun,
day = "30",
doi = "10.1183/16000617.0354-2020",
language = "English",
volume = "30",
journal = "European Respiratory Review",
issn = "0905-9180",
publisher = "European Respiratory Society",
number = "160",
}